RECRUITING

Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Description

Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called Restriction Spectrum Imaging (RSI-MRI) to evaluate whether RSI-MRI can predict treatment response.

Conditions

Prostate Cancer
Talk to us

Related Conditions:

Prostate Cancer

Study Overview

On this page

Study Details

Study overview

Adult male patients with high-risk, localized prostate cancer and planning to undergo radiation therapy (RT) with androgen deprivation therapy (ADT) will undergo an advanced Magnetic Resonance Imaging (MRI) examination called Restriction Spectrum Imaging (RSI-MRI) to evaluate whether RSI-MRI can predict treatment response.

A Phase II Biomarker Study of Restriction Spectrum Imaging (RSI) MRI in Patients With High-Risk, Localized Prostate Cancer Who Will Receive Radiotherapy and Androgen Deprivation Therapy

Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

La Jolla

UCSD Moores Cancer Center, La Jolla, California, United States, 92093

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male, aged ≥18 years, with histologically confirmed adenocarcinoma of the prostate
  • * High-risk prostate cancer (any of: PSA ≥20 ng/mL or cT3-T4 stage or Gleason score ≥8)
  • * Intended treatment and follow-up according to standard of care for prostate cancer
  • * Planning to undergo definitive radiotherapy with neoadjuvant and concurrent androgen deprivation therapy
  • * In good general health as evidenced by medical history and ECOG performance status 0-2
  • * Provision of signed and dated informed consent form
  • * Stated willingness to comply with all study procedures and availability for the duration of the study
  • * Prior radiotherapy to the pelvis
  • * Prior treatment for prostate cancer (cryotherapy, high frequency focused ultrasound, prostatectomy)
  • * Hip prosthesis
  • * Contraindication to MRI, per institutional requirements
  • * Technetium-99 bone scan showing no clear evidence of distant metastasis
  • * MRI or CT scan of the pelvis showing no clear evidence of bone or distant metastasis
  • * Another malignancy, unless in remission or unlikely to impact the patient's survival or ability to receive standard care for prostate cancer (e.g., cutaneous basal cell carcinoma)
  • * Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Diego,

Tyler Seibert, MD, PhD, PRINCIPAL_INVESTIGATOR, University of California, San Diego

Study Record Dates

2026-12-01